SFM
BPMC

Sphera Funds Management’s Blueprint Medicines BPMC Stock Holding History

Sphera Funds Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-109,500
Closed -$6.4M – 94
2020
Q1 		$6.4M Buy
109,500
+3,500
+3% +$225K 0.8% 29
2019
Q4 		$8.49M Buy
106,000
+63,500
+149% +$4.75M 0.7% 23
2019
Q3 		$3.12M Buy
+42,500
New +$3.67M 0.48% 57

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sphera Funds Management's BPMC Position: Q2 2020 in Review

Sphera Funds Management sold out of Blueprint Medicines (BPMC) in Q2 2020, closing a stake of 109,500 shares — an estimated $6.4M sold.

Sphera Funds Management first reported a position in BPMC in Q3 2019 and held it in 3 quarters. The position peaked at $8.49M in Q4 2019. 234 funds tracked by Wall St. Rank hold BPMC as of Q2 2020.

  • Sphera Funds Management reported no remaining Blueprint Medicines position as of Q2 2020 after selling out during the quarter.
  • Sphera Funds Management sold 109,500 Blueprint Medicines shares in Q2 2020, an estimated $6.4M.
  • Sphera Funds Management first reported a position in Blueprint Medicines in Q3 2019 and held it in 3 quarters.
  • Sphera Funds Management's Blueprint Medicines position peaked at $8.49M in Q4 2019.
  • 234 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2020.

Based on Sphera Funds Management's 13F filing for Q2 2020, filed 13 Aug 2020.